In a clinical trial, the drug, acoramidis, had a survival rate of 81 percent after two and a half years, compared to 74 percent among patients who received a placebo, according to a July 17 BridgeBio Pharma news release. The drug also reduced risk of cardiovascular-related hospitalization by 50 percent.
Transthyretin amyloid cardiomyopathy occurs when a “misshapen version of a naturally occurring human protein gets deposited in the heart,” Bloomberg reported. The condition is becoming relatively common with about 5,000 to 7,000 new cases annually. The condition is “increasingly recognized cause of heart failure,” Muriel Finkel, president of Amyloidosis Support Groups advocacy group, told Bloomberg.
The company will file for U.S. market clearance by the end of 2023.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
